%0 Journal Article
%T Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.
%A Wang Y
%A Branco RF
%A Salanitro M
%A Penzel T
%A Schöbel C
%J Sleep Breath
%V 27
%N 1
%D 03 2023
%M 35486312
%F 2.655
%R 10.1007/s11325-022-02623-0
%X This study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF).<BR>In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.<BR>Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).<BR>In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.